INTRODUCTION
Cardiovascular diseases are the human diseases with the highest death rate. Atherosclerosis is one of the major underlying causes of cardiovascular diseases. In recent years, the suggestion that inflammatory mechanisms are importantly involved in atherogenesis has been substantiated by many investigations. Innate immune mechanisms, employing monocytes, innate cytokines, or chemokines are involved in the early steps of atherogenesis, whereas components of the adaptive immune system, such as T-cells, B-cells, or TH1 cytokines have been identified to be important in later periods of atherosclerosis. These observations indicate that inflammatory pathways potently contribute to the initiation and acceleration of atherosclerosis. Among the inflammatory pathways the cytokines are central players. Plasma levels of cytokines and related proteins, such as CRP, have been investigated in cardiovascular patients; tissue mRNA expression was analyzed, and correlations to vascular diseases established. Consistent with this suggestion, the generation of cytokine-deficient animals has provided direct evidence for a role of cytokines in atherosclerosis.
Further support for the suggestion that cytokines and other innate mechanisms contribute to atherogenesis can be derived from in vitro cell-culture experiments. These investigations show that cardiovascular cells, such as endothelial cells and smooth muscle cells are activated by exogenous (i.e. infectious agents or components thereof) or endogenous (i.e. PAMP-containing molecules or cytokines) triggers to produce cytokines. Among the activation pathways are innate mechanisms, such as toll-like-receptors (TLRs), including the endotoxin receptor TLR4. On the other hand, innate cytokines, such as IL-1 or TNF, or even autoimmune triggers may activate the cells.
Cytokines are potent activators of multiple cardiovascular cell functions relevant to maintain or spoil homeostasis within the vessel wall. Vascular cells, not least smooth muscle cells, can actively contribute to the inflammatory cytokine-dependent network in the blood vessel wall by production of cytokines, response to these potent cell activators and interaction with invading cells (monocytes, T-cells, mast cells) by these mediators. These pathways result in increased cell numbers and increased deposition of LDL-and ECM-components which may provide an 'immunovascular memory' resulting in an ever-growing response to subsequent invasion. Thus, vascular cells may potently contribute to the inflammatory pathways involved in development and acceleration of atherosclerosis.
In this review, we first focus on some pathophysiological aspects of atherosclerosis, outline the role of inflammatory and innate pathways for atherogenesis, and point to the importance of cytokine-mediated interactions of vascular and invading cells, by referring to data obtained in clinical, animal and in vitro settings.
ATHEROSCLEROSIS
Approximately 50% of all the deaths in Western societies are caused by diseases related to cardiovascular events, including stroke, heart failure, infarction or restenosis. Among the causes of stroke and heart failure, atherosclerosis is a major underlying disease. Atherosclerosis is a multifactorial disease and its pathogenesis is still not completely understood. Although it is more apparent in the elderly, it appears independent of race, age, nutrition and life-style. 1 However, atherosclerotic lesions in young people have been reported since the 1950s and onset of atherosclerosis may begin early in life and depend on various risk factors. [2] [3] [4] [5] [6] Among the classical risk factors are hypertension, hypercholesteremia, diabetes, smoking, metabolic syndrome, obesity and short-comings in physical activity. Comprehension of the pathogenesis of atherosclerosis in the two last decades has been greatly influenced by the proposal that inflammatory pathways are involved in the development and progression of atherosclerosis. Thus, formerly regarded as a lipid disease, more recently it has been suggested that inflammation, resulting from interference of modified lipoproteins or other activators with monocytes, T-cells and local vascular cells, is supposed to be the basis of atherogenesis. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In line with this, two major therapeutic approaches, one addressing plasma lipoprotein metabolism, the other pointing towards inflammatory processes, currently form the center of interest. 18 
Early phases of atherosclerosis

Inflammation and endothelial cell dysfunction
Changes in the vessel wall in early atherosclerosis may start with altered endothelial function, including vasoconstriction, enhanced procoagulation and enhanced leukocyte adhesion ('endothelial dysfunction'). There are findings that plasma proteins may enter the vessel wall to a higher degree than usual in early atherosclerosis. 19 On the other hand, 'patrolling' monocytes, 20 rich in CX 3 CR1, may enter the vessel wall and initiate the inflammatory response. Based on the 'response-toinjury' proposal by Ross, 8 the activation may be initiated by one or more of various pathways 21 such as altered response to flow, oxidized or otherwise modified LDL, homocysteine, bacterial antigens, bacterial membrane components (such as endotoxin [LPS]) or endogenous inflammatory signals like cytokines. Endothelial activation 22, 23 results in invasion of the vessel wall intima by leukocytes, migration and proliferation of local vascular smooth muscle cells and subsequent formation of an asymptomatic alteration of the vessel wall -the 'fatty streak'. Medical treatment may interfere with this progression of atherosclersosis. Statins slow the progression of atherosclerosis and even may reverse it. The major effect of this type of drug is attributed to lipid-lowering and endothelial improvement. 24, 25 With regard to the latter, it has been shown that statins also have anti-inflammatory effects. [26] [27] [28] On the other hand, the establishment of the fatty streak is also influenced by genetic parameters, including endothelial susceptibility, 29 variations in cytokine responses; 30, 31 altered responses to blood-flow; or the 'inflammatory burden' caused by infectious/noninfectious triggers. 32, 33 Among the exogenous and/or infectious activators, chlamydiae, HSV, CMV or EBV are candidates, whereas trauma, autoimmunity or cytokines may represent endogenous and/or non-infectious triggers ( Fig. 1A) .
Trigger mechanisms for the initiation of atherosclerosis -role of infectious agents
Although still discussed, evidence for a role of bacterial or viral infection in atherogenesis has been derived from different lines of investigation. [34] [35] [36] [37] [38] [39] [40] First, evidence for the presence of chlamydiae or viruses in the atherosclerotic vessel has been provided, 37, [41] [42] [43] [44] [45] although the infection rate of the vessel appears to be low. 46 Also, substances related to bacterial membranes, such as bacterial peptidoglycans, have been found in the vessel wall. 47 It is unclear whether the 'proposed causative infectious agent' causes its effect directly in the vessel wall, or promotes atherosclerosis indirectely by activation of systemic body responses, or both. All possibilities may exist, since vessel wall cells, such as ECs and SMCs, like some leukocytes, are capable of responding for example to Chlamydophila pneumoniae or chlamydial components. 48, 49 Also, T-cells, which respond to oxLDL or C. pneumoniae, have been isolated from the plaque. 50, 51 Another line of evidence for participation of infectious agents comes from the clinic. These data show that chronic respiratory, urinary or other infections conferred an increased risk of atherosclerosis, even in lowrisk subjects lacking conventional risk factors, 52 and that influenza vaccination decreased cardiovascular events in CAD patients. 40 Furthermore, epidemiological evidence showed that high endotoxin levels predicted an enhanced risk for atherosclerosis in smokers. 53 In the light of these studies, it does not appear very surprising that patients with a TLR4-polymorphism (Asp299Gly), which is associated with LPS-hyporesponsiveness, have been described by some investigators to have less coronary events, 54, 55 although others did not see such a correlation. 56 Further data supporting infectious and innate participation in initiation of atherogenesis can be derived from animal experiments. Rabbits infected with C. pneumoniae had an enhanced rate of atherosclerosis. 57, 58 Other experiments with rabbits showed that LPS (up to 2.5 µg LPS/animal), when repeatedly given intravenously, doubled lesion area and volume in hypercholesteremic rabbits. 37 Oral application of Porphyromonas gingivalis to ApoE-deficient mice resulted in increased infiltration, enhanced innate markers and larger lesions. Interestingly, this response was abolished in mice immunized with heatkilled P. gingivalis. 59 Finally, although the use of mice models for atherosclerosis studies may be discussed, the LPS-hyporesponsive mouse strain C3H/HeJ belongs to a group of animals least susceptible to atherosclerosis. 60, 61 On the other hand, it has been reported that germ-free mice still develop atherosclerosis. These findings, however, do not exclude that infectious agents can have a role in development of atherosclerosis, but they indicate that bacterial infection is not essential for the initiation of atherogenesis. 62 Thus, besides infectious pathways, endogenous pathways may exist, resulting in similar downstream mechanisms relevant for development of atherosclerosis (compare Fig. 1A ).
Trigger mechanisms for the initiation of atherosclerosis -endogenous activation mechanisms
The findings discussed above indicate a role for infection in atherogenesis; however, they do not exclude that other triggers may also contribute. As one possible endogenous trigger, autoimmune pathways are considered to be involved in atherogenesis. One line of evidence supporting this hypothesis comes from clinical observations: a variety of autoimmune diseases (such as SLE, rheumatoid arthritis or anti-phospholipid syndrome) are paralleled by enhanced cardiovascular morbidity caused by enhanced atherosclerosis. 63, 64 Possible candidates for autoimmune pathways of significance for atherosclerosis include heat shock protein 60 (HSP60), modified low density lipoprotein (LDL), β2glycoprotein-I (β2-gp-I) or protein tyrosine phosphatase LYP (PTPN22). [65] [66] [67] [68] Some of these antigens are not only a cause of auto-antibody production, but can also activate cell functions. In this regard, oxidized LDL has been shown to induce MCP-3 production in plaque monocytes, although not in SMC, 69 and it stimulates MCP-1 production in ECs and SMCs. 70 Induced by oxidative stress, LDL triggers oxygen radical formation by itself, resulting in a damaging cycle. 71, 72 oxLDL also stimulates SMC proliferation and cytotoxicity in SMCs and ECs depending on the LDL-dosis. 73, 74 Finally, and without claiming to be exhaustive, differentially modified types of LDL regulate production of cytokines, such as IL-6, in SMCs. 75, 76 The role of HSP60 in activating cytokine production in monocytes is controversial, since some of the previous results have been attributed to LPS-contamination. 77 However, it has been suggested that intracellular HSP60 may be involved in C. pneumoniae-activated proliferation of SMCs. 78 Little information exists regarding a role for β2-gp-I, although it has been shown that oxidized β2-gp-I induces dendritic cell maturation, which could be blocked by antioxidants. 79 Taken together, various situations or components, including infection, molecules of infectious organisms or endogenous molecules, appear to be initiators of early atherosclerosis. However, as also discussed for infectious causes of atherosclerosis, 80 it may be considered that not one particular trigger alone but rather several (in parallel or in sequence) cause changes that can eventually no longer be controlled or repaired ( Fig. 1B ). Under these conditions, the increasing cell-number and deposition of compounds, such as LDL and ECM may serve as an 'immunovascular memory' (IVM), resulting in evergrowing responses to subsequent invasion. A situation where the tissue is damaged irreversibly may be reached and atherosclerosis strides ahead merciless. The question of up to which time-point or situation these changes are still reversible and can be modulated (for example, by changes of life-style or by use of drugs) is unclear, but it could be that the process becomes irreversible when invasion of leukocytes is too high and wall architecture is destroyed (Fig. 1C, D) . 66 Loppnow, Werdan, Buerke Fig. 1 . The importance of repeated exogenous and endogenous activation of the vasculature for atherogenesis (schematically). (A) The normal vessel wall may be transformed into a pro-inflammatory state by a variety of parameters, including genetic, biochemical or biophysical factors. This makes it (more) receptive for further activation. An early effect in this pathway is the expression of adhesion molecules on the endothelium, resulting in the beginning of leukocyte invasion. (B) Upon activation of the endothelium, monocytes, mast cells, T-cells, as well as other cell types enter the vessel wall (red arrow). Also, plasma components may 'leak' increasingly into the vessel wall. Some monocytes (patrolling) may not settle, but depart again (blue arrow). Both, invaders and plasma components may result in further activation of the local cells. Repeated activations, possibly involving different kinds of activation (endogenous, exogenous, infectious, non-infectious) may take place subsequently. Frequency and potency of the activation may contribute to the force of atherogenesis. (C) Upon activation and invasion, cells interact with resident vascular wall cells, i.e. with neointimal and medial vascular smooth muscle cells. Subsequently, more SMCs migrate into the neointima. Many pathways involving synthesis of molecules are activated and, finally, foam cells are found and matrix production becomes visible. SMC also proliferate more potently and increase the wall thickness. The increased number of cells and matrix in the neointima may serve as an immunovascular memory (IVM), since it may result in an ever-growing response during subsequent invasion. (D) At a certain level of atherosclerosis, the endothelium disrupts, the neointima and other layers may obtain direct contact to the plasma. Finally, platelets may form clots, which, in the worst case, will cause stroke and heart attack.
Later phases of atherosclerosis
The later phases of plaque development are characterized by accumulation of various cell types in the vessel wall. During the establishment of the atherosclerotic plaque, many monocytes invade the vessel wall. The ratio of migrating and emigrating cells appears to be important for progression of plaque development ( Fig.  1B) . 81 It has been suggested that distinct subtypes of these cells, such as CCR2-CXCR1 ++ Ly-6C lo , enter and reside in the vessel wall. 82, 83 In the wall, monocytes eventually become lipid-laden macrophages, the socalled foam cells, which form a core region (Fig. 1C, D) . However, besides foam cells, which represent the numerically largest part of the invading cells, T-cells and other cells have been detected in the plaque. 11 It is now suspected that different subclasses of T-cells may have different effects on atherogenesis, some promote atherogenesis, whereas others mute it.
T-cells
Activated T-cells in the atherosclerotic plaque express the CD40-ligand (CD154). Interaction with CD40 + endothelial cells, SMCs and macrophages, induces expression of several pro-and anti-inflammatory molecules that have a role in atherogenesis and plaque rupture, such as cytokines, chemokines, growth factors, matrix metalloproteinases (MMPs) and procoagulants. Interestingly, blockade of CD40-ligand signalling reduced lesion formation, with a marked reduction in lipid and macrophage content. 84, 85 As discussed above, chemokines, including CXC-chemokines, are involved in the initial adhesion of monocytes to the activated endothelium. In response to CD40-ligand, additional chemokines, such as macrophage-derived chemokine, thymus-and activation-regulated chemokine (TARC, CCL17), eotaxin, interferon-inducible protein-10, fractalkine and other cytokines, such as IL-4, IL-12, IL-13, IL-18, or TNF are expressed in advanced human atherosclerotic lesions ( Fig. 2 ). 86 These mediators might affect plaque stability or plaque remodelling during the progression of atherosclerosis. Likewise, leukotriene B4 (LTB4) and 12,15-lipoxygenase products are important leukocyte chemo-attractants. Blocking their effects may also reduce atherosclerotic lesion development.
Mast cells
Among the cells also involved in atherogenesis are mast cells. The distribution of these cells has been investigated and they have been found in the adventitia, in fissures of atherosclerotic plaques or in the shoulder region. [87] [88] [89] It
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Fig. 2.
Production of inflammatory mediators in the later phases of atherosclerosis. Some of the cell types present in a typical atherosclerotic plaque are presented. Cell type-specific production of inflammatory mediators is indicated. Several chemokines, such as MCP-1, thymus-and activation-regulated chemokine (TARC), macrophage-derived chemokine (MDC) and others may attract monocytes and SMC into the subendothelial area. Other mediators, such as IL-4, IL-6, IL-12, IL-13, IL-18 or TNF-α are also expressed in the advanced human atherosclerotic lesion in response to cell interaction, including activation via CD40L, and may contribute to further activation of the cells within the plaque. The produced mediators affect plaque stability and plaque remodelling, and may potently contribute to plaque stabilization, or, in the worse case, to thrombus formation or plaque rupture. The cell types used (except T-helper-cells) are explained in the caption to Figure 1. had been proposed already in the 1950s that mast cells may have a role in atherosclerosis. 90 Although their role in atherosclerosis remained obscure until recently, functional evidence for their contribution has now been derived by various experimental settings, [91] [92] [93] [94] including experiments with mast cell-deficient mice. 95 The latter study by Sun et al. 95 indicated that mast cell-derived IL-6 and/or interferon-γ may contribute to the observed mast cell effects by activation of proteolytic enzymes. Indeed, mast cells can produce a variety of cytokines, including IL-1, 96 IL-6, 97 IL-8, 98 or TNF-α. 98, 99 Mast cells, as well as other cell types, may contribute to plaque vulnerability in late atherosclerosis by production of cytokines and, subsequently, by production of enzymes, such as matrix metalloproteinases, cathepsins, chymases or other pro-atherogenic proteases. It has been pointed out that the vulnerability of the plaque in the late phase of atherosclerosis is a very critical element in the fatal outcome of atherosclerosis in many cases. Inflammation and the resulting activation of proteolytic enzymes has been suggested to be an important determinant of plaque stability, and the establishment of treatments intending to reduce the vulnerability of the plaque (and the patients) has been recommended. 100
INFLAMMATORY AND INNATE PATHWAYS IN
ATHEROSCLEROSIS
We have already mentioned that inflammatory pathways (innate and cytokine pathways) are involved in atherogenesis. Historically, the terms 'calor, dolor, rubor, tumor and functio laesa', referring to heat, pain, redness, swelling, and dysfunction, described the expression of inflammation in the body. At first glance, these characteristics may not be central to atherosclerosis. 101 Thus, until recently, inflammation was not directly linked to vascular diseases. Only in the last two or three decades has inflammation been brought to the attention of researchers and clinicians interested in atherosclerosis. We know now that heat, pain, redness and swelling are caused by substances produced and released from cells. Involved in these incidents are substances such as cytokines, complement factors, prostaglandins, leukotrienes, bradykinins, or histamine. Although many of these factors contribute to inflammation, and may be involved in the regulation of the inflammatory cascades, 102 it is beyond the scope of this summary to discuss them all and we focus on the role of innate cytokines, innate receptors and cytokine-mediated cell interaction in cardiovascular diseases. During the inflammatory processes, many body functions are impaired: electrolytes are disturbed, leukocytes are attracted and extravasate, complement is activated, thrombocytes are activated, and the protein composition of the acute phase system is altered.
Cytokine and innate pathways as potent mediators of inflammation
Many of the above-mentioned inflammatory functions are regulated by cytokines. These mediators, produced by leukocytes and tissue cells, are very potent regulators of cell functions and many are thought to be involved in atherogenesis (some examples are given in Table 1 ). Originally, they have been described as monocyte or lymphocyte products (monokines or lymphokines, respectively), however; we know now that many tissue cells also produce cytokines. [103] [104] [105] [106] [107] [108] [109] [110] The term cytokine is derived from the Greek words κψτοσ (cyto; cell) and κινειν (kinesis; movement) meaning 'working on and between the cells'. The terms 'cytokine' 107 and 'interleukin' 104 were coined in the 1970s. Early studies in the cytokine field were concerned with growth factors, 111 interferons (chorio-allantoic cells produced interferon in response to viruses), 112 colony stimulating factors, 113 lymphokines 108 or monokines, such as TNF 114, 115 or IL-1. 109, [116] [117] [118] 
Inflammatory steps in atherosclerosis
From the elegant recent review by Libby, 119 one can derive major inflammatory steps involved in plaque evolution:
1. Activation of adhesion molecules, such as VCAM, on the endothelium. 68 Loppnow, Werdan, Buerke 3. Accumulation and further attraction of cells by chemokines, including MCP-1.
4. Transformation of monocytes to foam cells in response to cytokines, such as M-CSF.
5. Alteration of plaque stability by cytokine-mediated enzyme production, the resulting modification of the fibrous cap, and, in the worst case, rupture of the plaque and thrombosis, resulting in stroke or myocardial infarction.
Interaction of cells by cytokines
Under the described conditions, the invading leukocytes may interact at many steps with the local vessel wall cells by means of cytokines. The activation and interaction is a central point of Figure 1 and may result in further local production of various chemokines and cytokines. Cytokine production may be activated by (exogenous) micro-organisms, components of microorganisms or other (endogenous) danger signals. It became clear in the 1990s that vascular cells, including smooth muscle and endothelial cells, can produce cytokines and potently react with these mediators of immunity and inflammation, thereby contributing to inflammatory pathways. [120] [121] [122] [123] [124] [125] 
Initiation of the atherosclerotic processcontribution of innate receptors
The hypothesis that cytokine and innate pathways are involved in pathogenesis of cardiovascular diseases and, in particular, in atherosclerosis, has evolved in the last two or three decades. The first evidence was provided by measurement of cytokines in the plasma of patients. [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] These data showed correlations of plasma levels of proinflammatory cytokines, such as IL-1, IL-6 or TNF, as well as other molecules related to inflammation, such as CRP or HSP60, with several cardiovascular diseases. On the other hand, mRNA expression of cytokines or innate molecules in various cardiovascular tissues has been investigated. 65, 125, [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] More direct evidence for a role of cytokines or molecules related to innate pathways in atherogenesis has been derived in experiments with atherogenesis-prone mice (i.e. LDL-receptor-deficient or ApoE-deficient mice) containing an additional (i.e. cytokine or innate) deficiency. These double-null mice contain a LDLreceptor-or ApoE-deficiency that makes them develop atherosclerosis if they are fed on a defined diet. The respective cytokine/innate knockout in the double-null mice shows the effect of the given cytokine/innate protein on atherosclerosis. As indicated above, there are various steps (activation, adhesion, invasion/chemotaxis, further activation) finally leading to the atherosclerotic plaque, independent of whether or not it will become a dangerous, thrombogenic plaque. In addition, for all functions of the cytokines and innate pathways, intracellular signalling molecules are necessary. These processes are also potential targets of transgenic experiments. For a variety of the components involved in the above mentioned pathways, double-null mice have been developed, and will be included in the following discussion.
Innate receptors
As pointed out above, infectious pathways may contribute to initiation of atherosclerosis. Since infectious 'agents', such as bacteria or viruses, are already recognized by the first line of defence of the body (the innate immune system), we shall consider some components of the innate immunity in more detail ( Table 2 ). The innate system is not unspecific, although it has a much smaller repertoire than the adaptive immune system but, it recognizes defined types of activators. In addition to these 'pattern recognition molecules' (PRMs) discussed here, natural antibodies and the complement system also belong to the innate defence system (but are not discussed further). Many infectious 'agents' activate cells via the PRM by PAMP (pathogen-associated molecular pattern) containing molecules. PAMPs are highly conserved structures of micro-organisms, or other 'danger signals', indicating 'a need for' defence. Among these activation pathways are soluble mechanisms, the pentaxin or pentraxin molecules, including the acute phase molecules and serum proteins CRP or SAP. Other recognition molecules are present in the cytosol of cells, including the NOD-like receptors (NLRs; for example, NODs, NALPs, IPAF, NAIP), 150 and may contribute to the function of the inflammasome, thereby enhancing the inflammatory/innate response. Finally, numerous bacterial or viral components are recognized by membrane-associated molecules, the toll-like receptors (TLRs). These three groups of 'pattern recognition molecules' are also called pattern recognition receptors, in a more constrained fashion; however, not all of these molecules are membraneassociated.
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Innate pattern recognition molecules -pentraxins
The pentraxins (or pentaxins) are soluble proteins present in the plasma. CRP and SAP belong to the short pentraxins, whereas PTX3 is the prototype of a long pentraxin. 151 The short pentraxins are mainly produced in the liver. PTX3 is produced by many cells including monocytes, fibroblast or vascular cells, and its activation is induced by IL-1, TNF, LPS or oxLDL. 152, 153 PTX3 is a multifunctional protein contributing to ECM deposition and inflammation by binding to one of various possible ligands, such as complement factors, ECM, growth factors, membrane components or pathogens. 151 Subsequently, PTX3 can activate the complement cascade, as well as the removal of pathogens or cellular debris. PTX3 has been detected in the atherosclerotic plaque in monocytes, endothelial cells and, to a lesser extent, in smooth muscle cells. 154 Furthermore, its expression is regulated in different types of SMC, possibly via cytokines, 155 but also by E-LDL. 152 Very recently, this molecule has been described as a marker of inflammation in patients with heart failure, 156 as well as myocardial infarction. 151, 157 
Innate pattern recognition molecules -NOD-like proteins/ receptors (NLR)
The NOD-like proteins belong to a group of proteins containing a 'nucleotide-binding oligomerization domain' (NOD). They are cytoplasmic proteins potently involved in innate immune responses and inflammation. Basically, these proteins bind pathogen-derived molecules and either activate MAP-kinases or NF-κB (NOD1, NOD2), or activate caspase-1 (NALP1, NALP3, IPAF) by triggering the assembly of the inflammasome, a multiprotein complex important for activation of IL-1, IL-18 and IL-33. The NOD-like molecules have been described in detail in recent reviews. 150, [158] [159] [160] [161] [162] [163] The activation of the inflammatory network by NLRs may contribute to cardiovascular diseases, but few data are yet available. However, it has been described that NOD1, but not NOD2, agonists activated smooth muscle cells, indicating the presence of NOD1 pathways in vascular SMCs. 164 Activation of NOD1 in this case may lead to NO production and vascular dysfunction.
Innate pattern recognition molecules toll-like receptors (TLRs)
The TLRs are related to the Drosophila receptor toll, and to the IL-1 receptors. 165, 166 Interestingly, toll shares with the TLRs and the IL-receptors a signal pathway related to NF-κB (dorsal) and I-κB (cactus), and all three pathways (toll, TLR, IL-1) contribute to defence mechanisms in the respective organism (Fig. 3 ). The first of the TLRs discovered was TLR4, the receptor for Gramnegative endotoxin (LPS). 167 There are 10 human and 13 murine TLRs described, besides many parallel or different TLRs in other species. 168 The TLR molecules contain leucine-rich-repeats (LRR) outside the cell, a transmembrane domain and an intracellular TIR-(toll/IL-1-receptor) domain. Various adapter molecules (MyD88, NOD, MAL, TRIF, TRAM, etc.) are necessary for the intracellular signaling of the respective TLR molecules. The various TLRs, depending on their different PAMP-specificity, will bind different activators of microbial/viral origin, as well as endogenous activators (danger signals) of the host. Among the many TLRs, TLR2 and TLR4 are involved in innate processes relevant for initiation and or promotion of atherosclerosis.
TLR4 has been detected in the failing myocardium, 169 and in atherosclerosis expression of TLR4 (among others) has been identified in the plaque. [170] [171] [172] Besides endotoxin, heat shock proteins, 49 the fibronectin EDA domain, hyaluronic acids, lipoteichoic acids, and even modified forms of LDL, as well as saturated fatty acids 173 are recognized by TLR4. SMCs can express TLR4, and LPS-induced enhancement of its expression may be influenced by NADPH oxidase activation and mRNA stability. 174 Besides the exogenous stimuli, endogenous host molecules have also been shown to activate via TLR4. Thus, oxLDL up-regulates TLR4 expression. 171 In addition to TLR4 mRNA, arterial SMCs express mRNA for TLR3, TLR6 and, to some degree, for TLR1 and TLR5, but not for TLR7, TLR8, or TLR9 175 and TLR2. 176 On the other hand, endothelial cells express TLR4 and TLR2 [177] [178] [179] and, in TLR2-deficient mice, SMCs are protected against neutrophil-mediated injury. 180 Others reported that TLR3 is expressed constitutively and at higher levels than TLR2, TLR4, TLR7, TLR8, or TLR9 in retinal endothelial cells. 181 TLR5 has also been shown in microvascular endothelial cells. 182 Not only has TLR expression been investigated, but also transfection experiments with high-cholesterol fed rabbits and cultured SMCs showed that co-transfection with TLR2 and TLR4 enhances atherosclerosis, as well as NF-κB, MCP-1 and ICAM-1 in culture, respectively. 183 
Atherosclerosis-prone mice (i.e. LDL -/or ApoE -/-) containing an additional knockout of a pattern recognition molecule are less atherosclerotic
The above data show that plaque and vascular cells express various TLRs and can be activated via these molecules. Their role in atherosclerosis has been shown clearly in TLR-deficient mice. Compared with atherosclerosis-prone ApoE -/--(C57BL/6)-mice, animals also lacking TLR4 (ApoE -/-TLR4 -/-), or the TLR4 downstream signaling molecule MyD88 (ApoE -/-MyD88 -/-) had a smaller plaque area, but hypercholesterolemia was not reduced. These mice also had lower numbers of monocytes, lipids and COX2-immunoreactivity in their plaques, 184 indicating reduction of inflammatory components, but not circulating cholesterol or lipoproteins. In line with this, others reported that MyD88-deficient (ApoE -/-MyD88 -/-), but not CD14-deficient mice (ApoE -/-CD14 -/-) had reduced lesion area and macrophage recruitment. 185 More recently, a contribution of TLR2 in atherosclerosis has also been shown in Ldlr -/-Tlr2 -/mice. 186 These mice had lower cholesterol and lesion area, and bone marrow transplantation experiments suggested that vascular TLR-2 expression was important for atherogenesis in this model. The authors also suggested that recurrent microbial infection may influence disease severity by TLR2/TLR1 activation.
Taken together, the impact of the innate TLR molecules in atherosclerosis may not only be implicated in the activation of vascular cells by infectious agents, but may also be shown by the finding that endogenous, hostderived ligands of these highly conserved innate molecules activate the pathological process. The activation of cellular functions by PAMP-containing ligands, may they be exogenous or endogenous, finally results in the production of cytokines and other activities. Cytokines contribute to vascular pathology in many ways. An important facet of cytokine biology is the fact that some of these mediators, parts of the innate defence system by themselves (for example, IL-1 or TNF), once produced, perpetuate the inflammatory response by autocrine and synergistic mechanisms. This does not only implicate enhancement of the cellular response by minimal activation, but also takes into account the different genetic background of each person, since many of the genes involved have polymorphisms which alter the functionality in the given subject. Despite these very complicated interdependences, we summarize below some evidence for the contribution of the cytokine network to the development of atherosclerosis.
Role of innate cytokines in development of atherosclerosis
Activation of cells via innate pathways in the initial steps of atherosclerosis, as described above, may result in cytokine production. These potent mediators of inflammation have the capacity to regulate many of the functions/dysfunctions important for atherogenesis ( Fig. 4) , 125, 187 including expression of adhesion molecules or chemokines in vascular cells, activation of penetration and migration, stimulation of cell growth, or synthesis of new products, including matrix degrading enzymes. All these functions of cardiovascular Fig. 3 . Comparison of the TIR-containing receptors toll, IL-1-receptor and tolllike-receptors (TLRs). The intracellular part of the three receptor types contains a region (TIR, toll-IL-1-receptor domain) that is homologous. All three are involved in defence against pathogens. The ligand for the Drosophila molecule toll is 'spätzle', a cytokine-like molecule induced by fungi or bacteria in the fruit fly. The ligand for the IL-1-receptor in mammals, the cytokine IL-1, is induced by many activators, including microbial components. Finally, viral or endogenous components are the ligands for the pattern recognition molecules of the toll-like-receptor group. The signalling molecules presented in the lower panel reflect analogous steps in the different pathways. Ex, extracellular; In, intracellular; CYS, cysteine-rich domain; Ig, immunoglobulin-like domain. and invading cells collectively contribute and lead (in the worst case) to coronary plaque development and life-threatening plaque rupture.
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A variety of cytokines, including chemokines, proand anti-inflammatory cytokines (compare Table I ), as well as receptors for these molecules have been investigated in double-null mice. Furthermore, substances induced by the cytokines, such as enzymes relevant for matrix degradation, also have been investigated in atherosclerosis-prone mice. 188, 189 A great number of knockout experiments showed a reduction of atherosclerosis, but atherosclerosis was not completely reduced in any experiment, pointing to the importance of the interaction of several participating components. In the following, some of these data are elaborated.
The innate cytokines IL-1 and TNF-α
Two central mediators in the cytokine network are IL-1 and TNF-α. These two mediators contribute to the innate defence, with profound effects on cardiovascular cell functions. 190 IL-1β polymorphisms have been shown to influence the risk of infarction in young 191 or C. pneumoniae-infected 192 patients. Both, IL-1-and TNF-α-like molecules are already present in invertebrate defence. 193 IL-1 was originally described as a monocyte product. 194 Its production is activated by various stimuli including bacterial components, 195, 196 hypoxia, 197 oxidized LDL, 198, 199 or even itself. [200] [201] [202] IL-1 is multifunctional, 203 for example, it is involved in fever, synthesis of acute phase proteins, proliferation of various cells, as well as in activation of T-or B-cells. Many functions of IL-1 are mediated by secondary cytokines, such as IL-6 or chemokines. The two isoforms of IL-1 were cloned two decades ago. [116] [117] [118] The IL-1β gene was probably derived from a pro-interleukin-1α gene during evolution. 204, 205 IL-1 contains 12 β-sheets in a tetrahedron-or trigonalpyramid-like secondary structure, 206, 207 similar to basic fibroblast growth factor, 208 and the IL-1s and the FGFs are thought to have possessed a common ancestral gene 350 million years ago. IL-1ra diverged much later. 209 The IL-1 isoforms (IL-1α and IL-1β) are produced as 31-kDa precursor molecules and IL-1β is enzymatically (caspase-1; IL-1β converting enzyme, ICE) processed into its 17-kDa mature form. IL-1α can be expressed on the cell surface, 210 where it is functionally active on cardiovascular cells. 211, 212 In contrast to the IL-1α precursor, the IL-1β precursor is not (or a million-fold less) active. 213 In SMCs, IL-1β is not processed, 122 but leukocytes can activate the precursor present in SMCs in a cell number dependent fashion. 214 Most of the IL-1α activity remains cell-associated, whereas most of the IL-1β activity is released. 215 In the vessel wall, monocytes (as well as endothelial or smooth muscle cells) may express IL-1. 211, [216] [217] [218] The active IL-1 isoforms can induce a great number of functions in cardiovascular cells by specific mechanisms. [219] [220] [221] [222] In the heart, IL-1α overexpression has been shown to result in hypertrophy. 223 In endothelial and smooth muscle cells, IL-1 activates many functions important for atherogenesis. The expression of adhesion molecules on endothelial or smooth muscle cells, necessary for invasion, is potently activated by IL-1. [224] [225] [226] [227] [228] Also, production of chemokines necessary for invasion of leukocytes and retaining these cells in the wall, such as IL-8, 229-231 MCP-1, 230 or fractalkine 232 is regulated by IL-1. Within the vessel wall, IL-1 may activate proliferation of the local cells, 233, 234 an effect which is probably mediated or amplified by induction of PDGF. 235 IL-1 also induces NO-production in SMCs, 236 which may, in turn, contribute to regulation of proliferation and, thus, may be a candidate for gene therapy. 237 Induction by IL-1 of the production of many other molecules such as IL-6, 120,123,124 VEGF, 238 TGF, 239 endothelin, 240 scavenger receptors, 241, 242 or even radicals 243 may further enhance the inflammatory processes in the wall. Besides these effects on cardiovascular cells, IL-1 and TNF also inhibit contraction of vascular cells 244, 245 as well as heart cells, 246, 247 and both cytokines stimulate the production of the relaxants adrenomedullin 248 and nitric oxide. [249] [250] [251] [252] By means of the above-mentioned regulation of enzyme [253] [254] [255] and/or matrix production by cytokines, [256] [257] [258] [259] as well as by regulation of migration and proliferation, the cytokines may contribute to development of atherosclerosis. Deposition of matrix components, which, in turn, may stabilize or enhance LDL, lipoprotein, SMC or monocyte retention, 260 contributes to the 'immunovascular memory' effect proposed in Figure 1 . Briefly, ECM production is regulated differentially in response to various inflammatory mediators (such as IL-1, TGF, PDGF or TNF) in the cells relevant for atherosclerosis, such as monocytes or SMCs. Matrix components are important for migration, proliferation or lipoprotein retention, which are key events in atherosclerosis. 261, 262 During atherogenesis, ECM is produced by smooth muscle or other cells. Components of the ECM can bind a variety of cytokines. [263] [264] [265] [266] ECM or factors released from it, such as cytokines, can alter various cell functions. [267] [268] [269] [270] [271] [272] The 'immunovascular memory' proposal includes that ECM components can increase the retention of LDL or lipoproteins, 273 which can contribute to activation of SMCs or monocytes in atherogenesis. [274] [275] [276] [277] Thus, invading cells, ECM and the substances attached to it, may represent a reservoir for activation of cells invading the vessel wall in the future. Finally, monocytes or smooth muscle cells invading the wall at later time points are more potently restrained and activated by the existing components (growth factors, oxLDL, macrophages, SMCs, ECM), thereby establishing an unspecific 'memory' effect.
TNF-α shares many characteristics with IL-1. It is also produced by monocytic cells, it is a pleiotropic cytokine, it is also produced by cardiovascular cells, 278, 279 and it also can signal via NF-κB, to mention only some points. On the other hand, it is a member of a family of molecules, including (among others) CD40L, LIGHT, TRANCE, TRAIL, CD30L, FasL, mTNF, 4-1BBL, OX40L, CD70, which are preferentially membrane-bound. Their function, in many cases, needs cell-cell contact and they are capable of signalling in two directions (forward, by the ligand itself -death, survival, differentiation, inflammation; reverse, by the respective receptor -proliferation, cytokine secretion, oxidative burst, class switch). 280 In the case of TNF, this may even lead to monocyte desensitization to LPS. TNF is produced as a 26-kDa membrane-associated molecule and cleaved by a protease (TNF-converting enzyme, TACE) into its 17-kDa soluble form. It binds to its receptor as a homotrimer. Depending on the presence of the TNF-receptor subtypes I (p55) or II (p75), it induces NF-κB and/or the death pathway, or only the NF-κB pathway, respectively.
TNF/atherosclerosis-prone double-null mice are less atherosclerotic
The above data indicate that IL-1, as well as TNF, may have an important role in vessel wall function and dysfunction. This suggestion is further substantiated by investigations using mice deficient for these cytokines, their receptors or the IL-1 receptor antagonist. Thus, it has been shown that apoE/TNF-α double-null mice have less atherosclerosis than control apoE-null mice. 281 In these mice, the plaque area was approximately 30% smaller, and ICAM-1, VCAM-1, MCP-1, scavenger receptor and macrophage oxLDL uptake were reduced, although the cholesterol level was not altered. Likewise, in a TNF-receptor p75/apoE double-null model, the lesion area was also reduced. 282 Interestingly, blocking another TNF-receptor family member related to the adaptive immune system, important for T-cell activation, the OX40, also resulted in reduction of the lesion area. 281 
IL-1/atherosclerosis-prone double-null mice are less atherosclerotic -experimental evidence for a role of the other proteins of the IL-1 family in atherosclerosis
A 30% reduction of the lesion area was also observed in apoE/IL-1β double-null mice, accompanied by a reduced VCAM-1 and MCP-1 level, despite no changes in body weight or lipid levels. 283 More recently, bone marrow transplantation experiments from IL-1α -/or IL-1β -/mice into irradiated wild-type mice showed reduced lesion area and plasma SAA, and reduced lesion area in atherogenic diet-fed IL-1α -/or IL-1β -/mice. 284 IL-1 activities are mediated by the IL-1 receptor type 1. Lack of the IL-1-receptor type 1 gene in apoE +/mice resulted in an enormous reduction of lesion size, both in uninfected mice (78%), as well as in P. gingivalisinfected mice (97%). 285 Further evidence for a role of IL-1 in vessel wall inflammation comes from experiments with the IL-1-receptor antagonist. IL-1ra-deficient mice presented with enhanced neointimal thickening after injury. 286 This result was verified by the finding that IL-1-receptor type 1-null mice, as well as IL-1β-null mice expressed a reduced neointima/media ratio in ligationinduced neointima formation. 287 Atherosclerosis-prone mice (apoE-null) containing less IL-1ra (IL-1ra +/-) expressed a significantly increased lesion size, as compared to IL-1ra +/+ mice, 288 in keeping with LDLrec/IL-1ra double-null mice. 289 On the other hand, application of IL-1ra or TNF-binding protein to diet-treated ApoEnull mice resulted in reduced lesion area. TNF-bp had a lower effect compared with IL-1ra and was inactive in male mice. 290 Finally, investigating a homozygous IL-1ra knockout, instead of a heterozygous 288 Merhi-Soussi found massive inflammation and early mortality in the ApoE double-null mice. 291 The authors suggested that the ratio of IL-1 and IL-1ra may be of great importance for the development of atherosclerosis. The ratio of IL-1 and IL-1ra has been proposed to be important in cardiovascular diseases, 143, 292 and in other diseases. [293] [294] [295] The above data indicate that the innate cytokines TNF-α and IL-1 may contribute potently to atherosclerosis. However, we suggest that these cytokines, in particular IL-1, may not provide their contribution to development of atherosclerosis by a single powerful activation, but rather by repeated (chronic), low or moderate interferences. As discussed above, these multiple interferences may not only be derived by one type of activation, for example an infectious incident, but by several and different activations, such as endogenous activation via TLR, as well as infections and bacterial components (see Fig. 1 ). Even smoking or renal dialysis may be included in the orchestration involved in these activation steps. 58 An analogous concept has been suggested to be responsible for the age-dependent changes observed in immunosenescence. In this field of research, an age-dependent increase in innate immunity and a loss of adaptive immunity is described. 296 Multiple infectious or inflammatory incidents ('multiple hits') cause an enhanced 'inflammatory/pathogen burden', resulting in an enhanced risk of cardiovascular diseases. 32, [297] [298] [299] [300] [301] 
Evidence for a role of MCP-1 and fractalkine in atherosclerosis
A number of chemokines are produced in the vessel wall which may contribute to atherogenesis. 302, 303 Among them are fractalkine and MCP-1. For both, animal experiments have been performed showing their potent influence on atherosclerosis. MCP-1 is expressed in atherosclerosis. 304 A role for MCP-1 has been shown in ApoE/CCR2 doublenull mice, lacking the MCP-1 receptor CCR2, since these mice developed smaller lesions. 305 Likewise, a knockout of MCP-1 in LDL receptor-deficient mice also reduced atherosclerosis. 306 In accordance with this result, mice overexpressing MCP-1 had larger lesions and more invading monocytes compared with control mice. 307 Furthermore, mice overexpressing ApoB, characterized by low enhancement of cholesterol but increased diet-induced atherosclerosis, if crossed with MCP-1-deficient mice, were protected from lesion development. 307 The chemokine fractalkine is unique, since it can function as a cell-associated adhesion molecule and, in its soluble form, as a chemokine. 308, 309 It is expressed on ECs 310 and SMCs. 232, 311, 312 Furthermore, fractalkine and its receptor are expressed in atherosclerotic lesions, 313, 314 and in the plasma of CAD patients. 315 Interestingly, soluble IL-6-receptor inhibited the expression of fractalkine in ECs. 316 The cleavage and release of fractalkine from the cell surface is processed by enzymes such as TACE, 317 or ADAM-10 and ADAM-17. 318, 319 Fractalkine receptor/ApoE double-null mice had reduced lesion formation, and less monocytes in the lesions. Smooth muscle cells, but not monocytes, of these mice potently expressed fractalkine. 320 On the other hand, fractalkine-deficient mice also had reduced atherosclerosis; however, in this model, atherosclerosis was more pronounced at the brachiocephalic artery as compared with the aortic root. 321 
IL-6 activates innate pathways and is produced by cardiovascular cells
Among the secondary cytokines produced in response to IL-1 or TNF-α, IL-6 is of major interest, since this cytokine is an important activator of the acute phase response. 322, 323 IL-6 activates the production of acute phase response proteins in hepatocytes. Some of these molecules (CRP, SAP) belong to the innate 'pattern recognition (receptor) molecules' called pentaxins or pentraxins, present in the plasma (compare above). 151, 324 Among its multiple functions, CRP can bind to various pathogens and it can activate the complement system, another facet of the innate defence system. IL-6 potently activates production of these molecules. [325] [326] [327] IL-6 is produced by a variety of cells, including monocytes, 328, 329 epithelial cells, 121 and cardiovascular cells. 120, 123, 124, 330 
Fig. 5.
Vascular smooth muscle cells produce more IL-6 than mononuclear cells. Human vascular smooth muscle cells (SMCs) were isolated from unused portions of saphenous veins used for bypass surgery. The cells were cultured in DMEM supplemented with 10% fetal calf serum, 1% antibiotics and 1% L-glutamine, and stimulated in an overnight culture. Human mononuclear cells (MNC) were isolated from heparinized human whole blood by Ficoll-gradient centrifugation and stimulated accordingly. SMCs (20,000 cells/cm 2 ) or mononuclear cells (625,000 cells/cm 2 ) were incubated with the same stimuli and IL-6 was measured in ELISA. Note the different scales. Not all concentrations of stimuli have been investigated with both cell types. These data are included in order to emphasize the general difference in the level of IL-6 production that we have observed in SMC and MNC experiments. It has been detected in numerous independent (using either MNCs or SMCs) experiments under various stimulation conditions, as well as in numerous parallel culture experiments using both cell types in the same experiment. Furthermore, we obtained basically the same results, if we used aortic SMCs instead of venous SMCs, or monocytes instead of MNCs.
Enhanced IL-6 gene expression was also detected in rat heart cells upon ischemia/reperfusion and was reduced by a protease inhibitor. 331 In cardiovascular cells, IL-6 is induced by a variety of stimuli, with IL-1 as one of the most potent. 123 In our hands, IL-6 is produced much more potently in SMCs than in monocytes or other cells. In Figure 5 , a representative experiment with SMCs and MNCs is presented. SMCs produce up to 120 ng IL-6/ml culture medium, whereas the mononuclear cells produce no more than 8 ng/ml in the experiment shown here. LPS is the better MNC-stimulus, whereas IL-1 is the more potent SMC-stimulus, which may also be of importance in the in vivo situation. Vascular endothelial cells produce IL-6 in the range of MNCs (data not shown), although IL-1 stimulates them more potently than LPS (as in the case of SMCs). Other cytokines (such as MCP-1 or oncostatin M) have also been shown to induce IL-6 production in SMCs; 332, 333 vice versa, IL-6 may induce MCP-1 via STAT3-mediated mechanisms. 334 An autocrine loop for stimulation of SMCs by IL-6, involving trans-signalling mechanisms, has been suggested. 335 Thrombin has also been shown to increase IL-6 in SMCs, which may be of importance for local thrombosis in atherogenesis. 336 On the other hand, a variety of other factors possibly involved in atherosclerosis have also been shown to increase IL-6 production. These include hypoxia, 337 biomechanical stress, 338 oxidative stress, 339 heat shock proteins, 340 LPS via soluble CD14-mechanisms, 219, 220, 341, 342 angiotensin, endothelin, 343 serotonin, 344 complement complexes, 345 or even calcium channel blockers. 346 In addition, CRP also induced MCP-1 and IL-6 production in SMCs. 347 
Functions of IL-6 important for atherogenesis
Besides the autocrine effect of IL-6 on SMC activation 335 discussed above, stimulation of a number of IL-6-induced SMC functions have been described. Importantly, IL-6 can induce the proliferation of SMCs, [348] [349] [350] it reduces the contractility of the cells, 351 it may alter prostaglandin-E 2 production, 352 stimulate the migration of SMCs, 353 or induce MMP-9 secretion via a VEGF-dependent pathway, 354 as well as MMP-1 production. 355 Some clinical data also point to a role of IL-6 in cardiovascular diseases. Thus, IL-6 or CRP are of potential value as markers for cardiovascular diseases, such as CAD and atherosclerosis. 136, 137, 356, 357 It has been suggested that the balance between the anti-inflammatory IL-10, which may regulate IL-6, is of importance for atherogenesis. 358 The expression of IL-6 has been detected in the atherosclerotic lesion. [138] [139] [140] [141] 359 Animal experiments suggest a role for the IL-6 system in atherosclerosis
More direct evidence for a contribution of IL-6 to atherogenesis comes from experiments injecting IL-6 into several types of male mice fed normal or high fat diets for 21 weeks. 142 In these experiments the atherosclerosis-resistant non-obese diabetic mice developed no lesions, even upon IL-6-treatment, whereas atherosclerosis-prone C57Bl/6 and ApoE-deficient mice in the same setting showed an increased lesion size upon IL-6 administration. On the other hand, Schieffer et al. 360 showed reduced MMP-9 expression (although gelatinolytic activity, due to co-incident TIMP reduction still was higher), reduced monocyte recruitment, but (surprisingly) increased lesion size in the double-null mice, which expressed no IL-6, 360 and they, and others, proposed an atheroprotective role of IL-6. 360, 361 Furthermore, female ApoE/IL-6 double-null mice, fed for one year on a normal diet, also developed larger lesions than IL-6-expressing mice. 362 These authors suggested a twosided or biphasic effect of IL-6 on atherosclerosis; one unexplored, which is protective, and a further one which exacerbates atherosclerosis, as previously observed by Huber et al. 142 Another strategy to investigate IL-6 effects was attempted by using an IL-6-inhibiting agent. In contrast to the data by Schieffer et al. 360 , Madan et al. 361 , and Elhage et al. 362 , ApoE-null mice treated with the IL-6 reducing agent Am80 had smaller lesions than untreated mice, and reduced IL-6 levels. 363 The divergent results may be explained by different effects of complete (i.e. ApoE -/-IL-6 -/-) and only partial (i.e. ApoE -/-Am80 application) IL-6 inhibition.
IL-6 is a potent regulator of acute phase proteins. Its effects on atherosclerosis may be mediated by these proteins. Experiments using gp130-deficient mice provided evidence for a role of IL-6-induced acute phase proteins in atherosclerosis. gp130 is a key part of the IL-6-receptor system and its removal leads to premature death. However, a hepatocyte-specific gp130-deletion indicated that an acute phase response protein may contribute to enhanced atherosclerosis lesion size. 364 These authors suggested a role for SAA in CCL2-induction and subsequent attraction of monocytes, however, due to the possibly still present IL-6-effects on cells other than the hepatocytes, the above proposed atheroprotective effect of IL-6 may be present under these conditions also. Furthermore, a role for CRP was suggested by experiments with atherosclerosis-prone mice crossed with CRP-transgenic mice (>34% lesion size), 365 which expressed more CRP in the lesion and enhanced atherosclerosis. The authors proposed a pro-atherogenic effect of CRP.
Further data showing a role of IL-6 are derived from experiments using mast cell-deficient mice. 95 These mice developed less atherosclerosis, and a role for IL-6 and IFN-γ was indicated in adoptive transfer experiments, showing less enzyme activity (MMP/cathepsin) and less atherosclerosis in animals transplanted with mast cells from IL-6-or IFN-deficient mice, as compared with experiments using mast cells from wild-type or TNF-deficient mice. Both developed normal atherosclerotic lesions.
Since it was suggested that the ratio of IL-6 and the anti-inflammatory cytokine IL-10 may be of importance for atherogenesis, 360 IL-10-transgenic mice also have been investigated. In line with the IL-6 data shown above, 360 overexpression of IL-10 reduced the lesion size and cholesterol accumulation, as well as complexity of the core and the apoptosis of foam cells. 366 Furthermore, deletion of IL-10 enhanced disease in atherosclerosisprone mice, 367, 368 and bone marrow transplantation experiments. 369 Taken together, the above data indicate an important contribution of the IL-6 system in atherosclerosis, however, since the data of the various types of experiments are somewhat inconsistent (possibly caused by the differential experimental settings) and the contribution of SMC-or EC-derived IL-6 is unclear, the role of IL-6 still needs to be investigated in more detail.
Cytokine-mediated interaction of vessel wall cells and leukocytes
Vessel wall cells, in addition to the classical cytokine producers (the leukocytes), can also produce cytokines, such as IL-1, TNF-α or IL-6. It has been shown in the literature that cytokines stimulate cardiovascular cells to modulate an array of functions, including proliferation, contraction, migration or synthesis of new mediators or enzymes (see above, Table 1 , Fig. 4 ). Initially in the atherosclerotic process, emigrating cells, such as monocytes, T-cells or mast cells, interact with the endothelium. Subsequently, these cells contact the cells present in subendothelial layers, which may include smooth muscle cells, and in later phases leukocytes. These cells may potently interact in the vessel wall by means of cytokines, thereby perpetuating the atherosclerotis process (Fig. 6 ).
EC/monocyte interaction
There are a two investigations showing enhanced production of the monocyte attractant MCP-1 in both the ECs and the migrating monocyte, 370 as well as enhanced IL-8 production. 371 Both monocytes and ECs also produce PDGF upon interaction, probably by an IL-1-and TNF-dependent pathway, 372 as well as the potent cell activator GM-CSF. 373 Interaction of monocytes and the endothelium may further result in reduced NO-production, leading to lower dilatation. 374 It has also been shown that monocyte/EC co-cultures produced enhanced tissue factor, which may be of importance for thrombo-embolic problems. 375, 376 Also of potential importance for later steps in atherosclerosis, MMP-1 is upregulated in monocyte/EC co-cultures. 377 
SMC/EC interaction
Upon migration of SMCs into the subendothelial space, interaction of ECs and SMCs may result in further activation. The relevance of endothelial-smooth muscle interaction was provided in co-cultures on microporous membranes. In this model, the adhesion of monocytes to ECs was increased upon co-culture of ECs with SMCs. 378 It has also been described that the proliferation, 379 collagen production, 259 or chemokine production 380, 381 was elevated upon EC/SMC interaction. TGF-β production is regulated depending on the type of co-culture (bilayer or mix), 382, 383 and may have impact on adhesion molecule expression on SMCs, 384 or NO production. 385 
SMC/monocyte and SMC/T-cell interaction
Following invasion of the neointima, monocytes may interact with the local SMCs in various ways. An enhancement of VEGF was observed in monocyte/SMC interaction, which was partially mediated by soluble cytokines, such as IL-6. 386 PDGF production was also enhanced in co-culture experiments, 387 as well as production of the multifunctional factor HGF. 388 Besides the possibility of these molecules contributing to cell growth in the developing plaque, counter-balancing mechanisms of SMC proliferation, such as PG-E 2 or urokinase-type plasminogen activator, have also been reported. 389, 390 On the other hand, the production of enzymes was enhanced in co-culture models. 253, 355 Furthermore, an enhanced NO-production upon interaction was detected. 391 Not only monocyte/SMC interactions have been studied. In the later phases of atherosclerosis, T-cells are potently involved. Thus, it has been shown that T-cells and SMCs of several tissues interact in various ways. [392] [393] [394] Fig. 6. Immigrant vessel-associated leukocytes contribute to the evolving atheroma in various ways. Many of the cited effects are initiated by cytokines which may be produced in response to the interaction of immigrant and residential cells. In turn, the initiated effects may activate or alter vascular cell function.
The above data indicate that a variety of cytokinemediated interactions of immigrant cells and vascular vessel wall cells may exist, which have to be balanced very precisely, in order to maintain a 'normal' vessel. In the case of too many activation(s) (i.e. too high a frequency) or too potent an activation, control mechanisms may no longer regulate vascular hemostasis and malfunction may finally result in plaque-development or protrusion. Better understanding of the multiple interactions in the vessel wall may provide information about potential therapeutic points of vantage.
CONCLUSIONS
The summarized data suggest a potent contribution of innate mechanisms, such as inflammatory mediators (cytokines, chemokines) and pattern recognition molecules in atherogenesis. We hypothesize from our and the cited research that there is no single discrete incident, but rather many subsequent and probably different interferences in the vessel wall, or at the endothelium, which may result in activation of the endothelium and/or the subendothelial vessel wall cells, leading to increased invasion and decreased emigration of leukocytes. Enhanced accumulation of monocytes/macrophages and smooth muscle cells, as well as increasing levels of extracellular matrix components, resulting for example in enhanced LDL retention or more cells, may serve as an 'immunovascular memory' leading to an ever-growing response to reiterative invasion. The increasing interaction of local vessel wall cells with invading leukocytes may further enhance and reinforce inflammation in the vessel wall by potently regulating local cytokine production.
